CGS 15943 is an Orally Active Adenosine Receptor Antagonist
Hepatocellular carcinoma (HCC) is primary liver cancer and the third most common cause of cancer mortality worldwide. CGS 15943 blocks proliferation in hepatocellular carcinoma (HCC) and pancreatic cancer adenocarcinoma (PDAC) cell lines by inhibiting the PI3K/Akt pathway. Researchers test the adenosine A2 receptor antagonist CGS 15943 for cerebroprotective activity in...